Lunesta, Crestor, Sanctura Among New Products In UnitedHealth Registry
This article was originally published in The Pink Sheet Daily
Executive Summary
UnitedHealth subsidiary Ingenix announces 14 new products to be included in the Aperio postmarketing surveillance registry. By year-end, the company expects the registry will include all the recent NMEs used by more than 1,000 UnitedHealth patients.
You may also be interested in...
UnitedHealth’s i3 Unit Tapped By FDA To Provide Postmarketing Surveillance
The company is close to reaching additional deals with manufacturers for use of its i3 Aperio postmarketing surveillance drug registry.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter